Perrigo Co PLC Faces Upcoming Securities Class Action Deadline

On December 1, 2025, several outlets reported that investors holding Perrigo Company plc (NYSE: PRGO) securities purchased between February 27, 2023 and November 4, 2025 are facing a critical deadline in a pending federal securities‑law lawsuit. The lead plaintiff’s deadline is set for January 16, 2026, and the legal community is urging shareholders who suffered losses to secure counsel promptly.

Rosen Law Firm, a global investor‑rights practice, and its partners at Levi & Korsinsky and Glancy & Co. have issued a series of notices. These advisories stress that the “Class Period” – the window in which shares were bought – is still open for potential inclusion in the class action. The lawsuits allege that Perrigo failed to disclose material information, potentially violating the Securities Exchange Act of 1934.

Investor Response

The notices call upon shareholders to confirm their participation before the lead‑plaintiff filing deadline. Those who have experienced significant declines in PRGO stock value are encouraged to contact the law firms for counsel, as failure to act could jeopardize their ability to recover damages. The guidance has prompted several financial news outlets to discuss the implications for PRGO’s investor base.

Market Context

Perrigo’s market performance has been volatile in recent months. The stock closed at €11.61 on November 27, 2025, a modest decline from its 52‑week high of €29.31 (March 2, 2025) and only slightly above its 52‑week low of €10.505 (November 20, 2025). With a market capitalization of approximately €1.62 billion and a price‑to‑earnings ratio of 9.61, the company remains a modest‑cap player in the health‑care sector.

What Investors Should Do

  1. Verify Ownership Dates – Confirm that the purchase dates fall within the specified Class Period.
  2. Consult Legal Counsel – Reach out to one of the listed law firms (Rosen, Levi & Korsinsky, or Glancy & Co.) before the January 16 deadline to assess eligibility.
  3. Review Settlement Terms – If admitted to the class, evaluate the proposed settlement structure and potential recovery amounts.
  4. Monitor PRGO’s Stock – Keep an eye on any market developments that might affect the lawsuit’s outcome or the company’s valuation.

Outlook

While the lawsuit could lead to a monetary recovery for affected shareholders, it may also impact Perrigo’s future regulatory standing and investor confidence. The company’s core business—manufacturing and supplying over‑the‑counter healthcare products, infant formulas, branded OTC and generic pharmaceuticals—remains unaffected operationally. However, the legal proceedings underscore the importance of transparency and compliance in the pharmaceutical industry.

Investors who have lost money on Perrigo securities should act swiftly to secure representation, as the January 16, 2026 deadline marks a pivotal moment for the class action’s progression.